New data show commercially insured patients face increasingly high cost sharing for brand medicines

New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...
Read More
Executive order threatens R&D when we need it most to fight COVID-19

In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
Medicare’s 55th anniversary: Celebrating the success of Part D

Today, we are excited to bring you a special edition of our Medicare Catalyst series in honor of Medicare’s 55th anniversary. On this date in 1965, President Lyndon B. Johnson signed into law...
Read More
Payers subject 80% of new RA and MS patients to utilization management restrictions

A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...
Read More
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access...
Read More
PhRMA submits comments to CMS on Medicaid proposed rule

In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts on...
Read More
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19

Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19...
Read More
By the numbers: A look at the sourcing of API used in medicines consumed in the United States

There has been a lot of focus of late on where active pharmaceutical ingredients (APIs) for medicines are manufactured. While some may claim we are reliant on other countries, putting us at risk of...
Read More
New report explores setbacks that bring future cancer success stories

Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for patients. The Catalyst welcomes...
Read More
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries

A new study from Oxford Economics found the pharmaceutical industry retains a considerably smaller share of total spending on its products than other research-intensive industries, despite investing...
Read More
Three reasons why MedPAC’s latest Part D proposal would be bad for patients

The recently released Medicare Payment Advisory Commission’s (MedPAC) report to Congress recommends restructuring the Medicare Part D benefit and allowing plans greater flexibility to implement...
Read More
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states

Recently, Lori Reilly, Chief Operating Officer at PhRMA, participated in a podcast with the Council of State Governments (CSG) to discuss the important work the biopharmaceutical industry is doing to...
Read More
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
New initiative to bridge the gap on antimicrobial innovation

Today, more than 20 leading biopharmaceutical companies are launching the AMR Action Fund, a ground-breaking partnership to invest nearly $1 billion to ensure a robust and diverse pipeline of new...
Read More
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access...
Read More